摘要
目的应用替罗非班与依达拉奉右莰醇联合治疗急性脑梗死,观察其临床效果并分析对神经功能指标的影响。方法2021年1月至2024年12月,从本院神经内科选取80例ACI患者纳入研究,按随机数字表法分为两组(每组40例),对照组给予常规治疗及依达拉奉右莰醇治疗,观察组患者加用替罗非班,疗程为1~2周,评估临床效果、治疗前后相关炎症细胞因子、凝血功能指标、神经功能指标变化。结果治疗后,观察组血清超敏-C反应蛋白、中性粒细胞计数/淋巴细胞比值、FIB水平降幅大于对照组(P<0.05)。观察组患者凝血酶原时间(PT)、凝血酶时间(TT)、活化部分凝血酶时间(APTT)较同时间点对照组延长,血清D-二聚体(D-D)水平降幅较对照组明显(P<0.05),两组美国国立卫生研究院脑卒中量表(NIHSS)和改良Rannkin(mRS)量表评分与对照组同时间点对比,降幅更大(P<0.05)。观察组临床效果较对照组显著(P<0.05)。结论临床应用替罗非班与依达拉奉右莰醇联合治疗ACI,能有效降低患者炎症因子水平,改善凝血功能及神经功能缺损程度,临床效果确切,安全可靠。
Objective To observe the clinical effect of tirofiban combined with edaravone dexborneol in the treatment of acute cerebral infarction(ACI)and analyze its influence on neurological function indexes.Methods From January 2021 to December 2024,a total of 80 ACI patients from the Department of Neurology of our hospital were selected and included in the study.According to the random number table method,they were divided into two groups(40 cases in each group):the control group was treated with routine treatment and edaravone dexborneol,and the observation group was treated with tirofiban for 1-2 weeks.The clinical effect was evaluated,and the changes of related inflammatory cytokines,coagulation function and neurological function indexes before and after treatment were observed and analyzed.Results After 1-2 weeks of treatment,the levels of serum hypersensitive-C reactive protein,neutrophil count/lymphocyte ratio and FIB in the observation group decreased more than those in the control group(P<0.05).After treatment,the prothrombin time,thrombin time and activated partial thrombin time in the observation group were longer than those in the control group at the same time point,and the decrease of serum D-dimer level was more significant than that in the control group(P<0.05),the National Institutes of Health Stroke Scale and modified Rannkin scale scores of the two groups after treatment were lower than those of the control group at the same time point(P<0.05).The clinical effect of the observation group was significantly better than that of the control group(P<0.05).Conclusions The clinical application of tirofiban combined with edaravone dexborneol in the treatment of ACI can effectively reduce the level of inflammatory factors,improve coagulation function and neurological deficits,and the clinical effect is exact,safe and reliable.
作者
王伟松
WANG Weisong(Department of Neurology,Pizhou Hospital of TCM,Xuzhou,Jiangsu 221300,China)
出处
《中国医药指南》
2025年第32期126-128,共3页
Guide of China Medicine
关键词
急性脑梗死
依达拉奉右莰醇
替罗非班
神经功能
炎症因子
Acute cerebral infarction
Edaravone dexborneol
Tirofiban
Neurological function
Inflammatory factors
